AMENDMENTS TO THE CLAIMS

1. (Currently Amended) A tetrahydrobenzazepine of the ~~general~~ formula I



(I)

~~  ~~

~~(II)~~

in which

~~A is a single bond or CH_2;~~

~~B is a single bond or a group NR^3;~~

~~Y is a single bond, CH_2 or a group NR^3, where A, B and Y are not simultaneously a single bond;~~

Ar is an aromatic radical which is selected from phenyl and a 5- or 6-membered heteroaromatic radical having 1, 2, 3 or 4 heteroatoms which are selected independently of one another from O, N and S, where the aromatic radical may have 1, 2 or 3 substituents which are selected independently of one another from C_1-C_6-alkyl which is optionally substituted one or more times by OH, C_1-C_4-alkoxy, halogen or phenyl, or C_2-C_6-alkenyl which is optionally substituted one or more times by OH, C_1-C_4-alkoxy, halogen or phenyl, or C_2-C_6-alkynyl which is optionally substituted one or more times by OH, C_1-C_4-alkoxy, halogen or phenyl, or C_3-C_6-cycloalkyl which is optionally substituted one or more times by OH, C_1-C_4-alkoxy, halogen, phenyl or C_1-C_4-alkyl, or halogen, CN, OR^4, $COOR^4$, NR^5R^6, $CONR^5R^6$, NO_2, SR^7, SO_2R^7, $SO_2NR^5R^6$, COR^8, and phenyl which optionally has one, two or three substituents which are selected independently of one another from C_1-C_4-alkyl,

C_1-C_4-alkoxy, NR^5R^6, CN, C_1-C_2-fluoroalkyl or halogen, where phenyl and the heterocyclic radical may also be fused to a 5- or 6-membered aromatic or nonaromatic carbocycle, or phenyl may be fused to a 5- or 6-membered aromatic or nonaromatic heterocycle which has 1, 2 or 3 heteroatoms selected from O, N and S;

R^1 is hydrogen, C_1-C_8-alkyl, C_1-C_8-haloalkyl, C_2-C_8-alkenyl, C_2-C_8-haloalkenyl, C_2-C_8-alkynyl, C_2-C_8-haloalkynyl, C_1-C_8-alkylcarbonyl, C_1-C_8-haloalkylcarbonyl or substituted C_1-C_8-alkyl which carries a substituent which is selected from OH, C_1-C_4-alkoxy, C_1-C_4-alkylamino, ~~Di~~di-(C_1-C_4-alkyl)amino, phenyl, phenoxy, C_3-C_8-cycloalkyl and C_3-C_8-cycloalkyloxy, where the last four groups mentioned may optionally have one or more substituents selected from OH, CN, NO_2, C_1-C_4-alkyl, C_1-C_4-haloalkyl, C_1-C_4-alkoxy, C_1-C_4-haloalkoxy and halogen;

R^2 is hydrogen, halogen, C_1-C_4-alkyl, C_1-C_4-alkoxy, C_1-C_4-haloalkyl, C_1-C_4-haloalkoxy, OH, NO_2, CN, $COOR^4$, NR^5R^6 or $CONR^5R^6$;

R^3 is hydrogen, C_1-C_4-alkyl, C_1-C_4-alkoxy, C_1-C_4-alkylcarbonyl, phenyl, phenyl-C_1-C_4-alkyl or phenylcarbonyl, where phenyl in the last three radicals mentioned may optionally have 1, 2 or 3 substituents which are selected independently of one another from C_1-C_4-alkyl, C_1-C_4-haloalkyl, C_1-C_4-alkoxy and halogen;

R^4 ~~to~~, R^5, R^6, R^7, and R^8 are independently of one another H, C_1-C_6-alkyl which may carry a substituent selected from OH, C_1-C_4-alkoxy and optionally substituted phenyl, C_1-C_6-haloalkyl or phenyl, where R^6 may also be a group COR^9 in which R^9 is H, C_1-C_6-alkyl which is optionally substituted by OH, C_1-C_4-alkoxy or optionally substituted phenyl, or C_1-C_6-haloalkyl or phenyl, where

R^5 with R^6 may also together with the nitrogen atom to which they are bonded be a 5- or 6-membered saturated or unsaturated N-heterocycle which may optionally have a further heteroatom selected from O, S and NR^10 as ring member, where R^10 is hydrogen or C_1-C_4-alkyl;

the N-oxides of this compound, the physiologically tolerated acid addition salts of this compound and the physiologically tolerated acid addition salts of the N-oxides of formula I.

2. (Canceled)

3. (Canceled)

4. (Canceled)

5. (Canceled)

6. (Currently Amended) A tetrahydrobenzazepine of the ~~general~~ formula I as claimed in claim 1, in which R2 is hydrogen.

7. (Currently Amended) A tetrahydrobenzazepine of the ~~general~~ formula I as claimed in claim 1, in which Ar is phenyl which may be substituted ~~in the abovementioned manner~~ as claimed in claim 1.

8. (Currently Amended) A tetrahydrobenzazepine of the ~~general~~ formula I as claimed in claim 7, in which phenyl is unsubstituted or has 1 or 2 substituents, of which one substituent is arranged in the para postion relative to the variable ~~Y~~NR^3.

9. (Currently Amended) A tetrahydrobenzazepine of the ~~general~~ formula I as claimed in claim 7, in which the substituents on the phenyl are selected from C_2-C_6-alkyl, C_2-C_6-alkenyl, C_2-C_6-alkynyl and C_1-C_2-fluoroalkyl.

10. (Original) A compound as claimed in claim 1, wherein Ar is phenyl which carries a radical R^P which is located in the para position of the phenyl ring wherein R^P has the following formula $R^{P'}$:



wherein

Y is N, CH or CF,

R^{a1} and R^{a2} are independently of each other selected from C_1-C_2-alkyl, fluorinated C_1-C_2-alkyl, provided for Y being CH or CF one of the radicals R^{a}l or R^{a2} may also be hydrogen or fluorine, or

R^{a1} and R^{a2} form a radical $(CH_2)_m$ wherein 1 or 2 of the hydrogen atoms may be replaced by fluorine and wherein m is 2, 3 or 4.

11. (Currently Amended) A tetrahydrobenzazepine of the ~~general~~ formula I as claimed in claim 1, in which Ar is a 5- or 6-membered heteroaromatic radical having 1, 2, 3 or 4 heteroatoms which are selected independently of one another from O, N and S, where the heteroaromatic radical may be substituted ~~in the abovementioned manner~~as claimed in claim 1.

12. (Currently Amended) A tetrahydrobenzazepine of the ~~general~~ formula I as claimed in claim 1, in which R^1 has the ~~general~~ formula CH_2-R^{1a} in which R^{1a} is C_1-C_7-alkyl, C_1-C_7-haloalkyl, C_2-C_7-alkenyl, C_2-C_7-haloalkenyl, C_2-C_7-alkynyl, C_2-C_7-haloalkynyl or C_1-C_7-alkyl which has a substituent which is selected from OH, C_1-C_4-alkoxy, C_1-C_4-alkylamino, di-(C_1-C_4-alkyl)amino, phenyl, phenoxy, C_3-C_8-cycloalkyl and C_3-C_8-cycloalkyloxy, where the last four groups mentioned may optionally have one or more substituents selected from C_1-C_4-alkyl, C_1-C_4-haloalkyl, C_1-C_4-alkoxy and halogen~~, or C_1-C_4-alkoxy, C_1-C_4-alkylamino, di-C_1-C_4-alkylamino, phenyl, phenoxy, C_3-C_8-cycloalkyl or C_3-C_8-cycloalkyloxy, where the last four groups mentioned may optionally have one or more substituents selected from C_1-C_4-alkyl, C_1-C_4-haloalkyl, C_1-C_4-alkoxy, C_1-C_4-haloalkoxy and halogen~~.

13. (Currently Amended) A tetrahydrobenzazepine of the ~~general~~ formula I as claimed in claim ~~11~~12, in which R^{1a} is C_1-C_7-alkyl, C_2-C_7-alkenyl, C_2-C_7-alkynyl, C_3-C_8-cycloalkyl or C_1-C_7-fluoroalkyl.

14. (Canceled)

15. (Canceled)

16. (Currently Amended) A tetrahydrobenzazepine as claimed in claim ~~14~~1, wherein R^P is selected from a radical of the formula



wherein

Y is N, CH or CF,

R^{a1} and R^{a2} are independently of each other selected from C_1-C_2-alkyl, fluorinated C_1-C_2-alkyl, provided for Y being CH or CF one of the radicals R^{a1} or R^{a2} may also be hydrogen or fluorine, or

R^{a1} and R^{a2} form a radical $(CH_2)_m$ wherein 1 or 2 of the hydrogen atoms may be replaced by fluorine and wherein m is 2, 3 or 4;

and R^{1a} is ethyl.

17. (Original) A tetrahydrobenzazepine as claimed in claim 16, wherein R^P is selected from isopropyl, (R)-1-fluoroethyl, (S)-1-fluoroethyl, 2-fluoroethyl, 1,1-difluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, (R)-1-fluoropropyl, (S)-1-fluoropropyl, 2-fluoropropyl, 3-fluoropropyl, 1,1-difluoropropyl, 2,2-difluoropropyl, 3,3-difluoropropyl, 3,3,3-trifluoropropyl, (R)-2-fluoro-1-methylethyl, (S)-2-fluoro-1-methylethyl, (R)-2,2-difluoro-1-methylethyl, (S)-2,2-difluoro-1-methylethyl, (R)- 1,2-difluoro-1-methylethyl, (S)-1,2-difluoro-1-methylethyl, (R)-2,2,2-trifluoro-1-methylethyl, (S)-2, 2, 2-trifluoro-1-methylethyl, 2-fluoro-1-(fluoromethyl)ethyl, 1-(difluoromethyl)-2,2-difluoroethyl, 1-fluoro-1-methylethyl, cyclopropyl, cyclobutyl, 1-fluorocyclopropyl, 2,2-difluorocyclopropyl and 2-fluorocyclopropyl.

18. (Currently Amended) A pharmaceutical composition comprising at least one active ingredient selected from compound of the ~~general~~ formula I as claimed in claim 1, the physiologically tolerated acid addition salts of formula I, the N-oxides of compounds of the ~~general~~

formula I, and the physiologically tolerated acid addition salts of the N-oxides of formula I, where appropriate together with physiologically acceptable carriers and/or excipients.

19. (Canceled)

20. (Canceled)

21. (Canceled)

22. (Currently Amended) A method for treating a medical disorder susceptible to treatment with a dopamine D3 receptor ligand, said method comprising administering an effective amount of at least one compound as claimed in claim 1 to a subject in need thereof, wherein the medical disorder is selected from the group consisting of schizophrenia, depression, parkinsonism, and renal function disorders.

23. (Currently Amended) The method as claimed in claim 22, wherein the medical disorder is ~~a disease of the central nervous system~~selected from the group consisting of schizophrenia, depression and parkinsonism.

24. (New) The method as claimed in claim 22, wherein the medical disorder is a renal function disorders.